| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00449202 | Obesity | Drug: oleoyl-estrone (MP 101) | Manhattan Pharmaceuticals | Phase 2 | 2006-06-01 | 2007-03-16 |
| NCT00449254 | Obesity | Drug: oleoyl-estrone (MP-101) | Manhattan Pharmaceuticals | Phase 2 | 2006-10-01 | 2007-06-04 |
| NCT01260805 | Bioequivalence|Ethinylestradiol|Gestodene|Harmonet | Drug: Reference Drug|Drug: Test Drug | Pfizer | Phase 1 | 2010-09-01 | 2011-02-18 |
| NCT01089049 | Breast Cancer | Dietary Supplement: FemMED Breast Health Formula | Nutrasource Diagnostics Inc. | Phase 1|Phase 2 | 2009-08-01 | 2012-03-23 |
| NCT00623116 | Kallmann Syndrome | Drug: Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below) | Hospital for Children and Adolescents, Finland | | 2007-12-01 | 2008-02-13 |
| NCT00711607 | Healthy | Drug: nomegestrol acetate and estradiol | Merck Sharp & Dohme Corp.|CRS Mannheim GmbH | Phase 1 | 2007-05-01 | 2015-08-18 |
| NCT00864214 | Menopause | Drug: bioidentical hormone (Biest)|Drug: bioidentical hormone (Biest)|Drug: bioidentical hormone (Biest)|Drug: bioidentical hormone (Vivelle-Dot) | Mayo Clinic | Phase 1 | 2008-06-01 | 2012-01-12 |
| NCT00917735 | Breast Cancer | Drug: Green tea extract supplement|Other: Placebo | University of Minnesota - Clinical and Translational Science Institute|National Cancer Institute (NCI) | Phase 2 | 2009-07-01 | 2016-01-25 |
| NCT02463383 | Breast Cancer | Drug: Alcohol + ibuprofen|Drug: Alcohol + placebo | Professor Lars Ove Dragsted|Technical University of Denmark|University of Copenhagen | Early Phase 1 | 2013-09-01 | 2015-06-03 |
| NCT00668174 | Breast Cancer Prevention | Behavioral: Exercise | Fred Hutchinson Cancer Research Center | Phase 2|Phase 3 | 1997-01-01 | 2012-11-26 |
| NCT00866437 | Premenstrual Syndrome | Drug: Skin test panel|Drug: Skin test panel | EVE Medical Systems Ltd. | Phase 2 | 2009-04-01 | 2010-06-15 |
| NCT00873262 | Premenstrual Syndrome | Drug: Skin test panel and desensitization kit|Drug: Skin test panel and solvent | EVE Medical Systems Ltd. | Phase 2 | 2009-04-01 | 2010-06-15 |
| NCT00522262 | Breast Neoplasms | Behavioral: Aerobic exercise intervention | AHS Cancer Control Alberta|Canadian Breast Cancer Research Alliance|University of Alberta|University of Calgary | | 2002-06-01 | 2015-01-14 |
| NCT02100553 | Healthy | Drug: CE/BZA|Drug: Itraconazole|Drug: CE/BZA|Drug: CE/BZA|Drug: Itraconazole|Drug: CE/BZA | Pfizer | Phase 1 | 2014-04-01 | 2015-03-23 |
| NCT01817400 | Infertility, Female|Obesity | Other: Microdialysis|Dietary Supplement: Vascepa - Fish Oil|Drug: Aspirin|Drug: Pioglitazone | University of Colorado, Denver|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Early Phase 1 | 2013-03-01 | 2015-03-12 |
| NCT00470119 | Breast Cancer|Obesity|Weight Changes | Behavioral: behavioral dietary intervention|Behavioral: Exercise intervention | Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) | | 2004-12-01 | 2012-09-07 |
| NCT00491595 | Drug Toxicity | Drug: High Dose Soy isoflavones | University of North Carolina|National Cancer Institute (NCI)|University of North Carolina, Chapel Hill | Phase 1 | 2004-03-01 | 2007-06-25 |
| NCT00309855 | Aging | Drug: Placebo|Drug: Testosterone|Drug: Anastrazole|Drug: Dutasteride | Mayo Clinic|GlaxoSmithKline | Phase 1 | 2005-12-01 | 2012-07-27 |
| NCT01411644 | Premature Ovarian Failure (POF)|Incipient Ovarian Failure|Poor Response After Ovarian Hyperstimulation|Early Menopause|Hypergonadotropic Amenorrhea | UMC Utrecht|Erasmus Medical Center|Medical Center Alkmaar|University Medical Center Groningen|Leiden University Medical Center|Medisch Spectrum Twente|Isala|Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.|Amphia Hospital|Deventer Ziekenhuis|Catharina Ziekenhuis Eindhoven|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Academisch Ziekenhuis Maastricht|VU University Medical Center | | 2005-01-01 | 2015-12-02 |
| NCT02892942 | Infertility | Drug: Gonal-F|Drug: Cetrotide|Drug: Cetrotide | Assistance Publique - Hpitaux de Paris|MerckSerono Pharmaceuticals | Phase 4 | 2016-09-01 | 2016-09-01 |
